Purpose-built as a GxP-ready ecosystem, our platform helps BioPharma teams meet regulatory requirements with confidence—backed by trusted data integrity, security and quality.
GxP compliance is engineered into everything we do
IDBS Polar is more than a platform—it’s a GxP-ready ecosystem
IDBS Polar is a next generation enterprise lab informatics software platform that unifies ELN, LES and LIMS capabilities into one powerful data management platform purpose-built for regulated labs.
Confidence in Compliance—Built In, Not Bolted On
With 20+ years of experience and a purpose-built GxP framework, we help you reduce validation burden, accelerate compliance and stay audit-ready—always.
End-to-end GxP compliance
A complete GxP framework covering people, processes, products and services ensures regulatory confidence.
Expert-led GxP governance
The IDBS GxP Guild, a cross-functional team, drives regulatory alignment, product roadmap input and internal awareness to stay ahead of compliance trends.
Built-in compliance features
Role-based access, audit trails, electronic signatures and record versioning are embedded to meet FDA 21 CFR Part 11 and EudraLex Annex 11 standards.
Streamlined validation & change control
Automated IQ/OQ and advisory services reduce customer validation burden and support seamless upgrades and change management.
Learn why IDBS is top rated for GxP Compliance
Learn how IDBS approaches GxP and supports your compliance needs in this whitepaper: Achieving compliance with confidence: The IDBS GxP framework
“Working with IDBS in general is always a pleasant experience. They are very attentive to our needs.”
Jennifer C
Operational Effectiveness Manager
Pharmaceuticals
Source: Capterra
“The audit trails are amazing and it’s really becoming a selling point.”
April Pisek
Associate Director, Product Owner, IDBS Platform
IQVIA Laboratories
Source: i3 interview
“Upgrading to Polar went very smoothly and we are very happy with the product overall.”
Jennifer C
Operational Effectiveness Manager
Pharmaceuticals
Source: Capterra
“IDBS Polar provides the ability to capture our data with integrity and quality built in for our end users.”
Jennifer C
Operational Effectiveness Manager
Pharmaceuticals
Data integrity for BioPharma:
why it matters
Watch our recent webinar: Unlocking data integrity: Proven strategies for GxP compliance and inspection readiness
GxP Resource Hub: Your guide to GxP compliance excellence
These resources offer practical insights into effective data management and regulatory compliance strategies.
How the IDBS GxP framework supports your compliance needs
Proven strategies for navigating GxP compliance
How a digital platform helps BioPharma labs achieve and maintain GxP compliance
IDBS at a glance
35 Years
Experience delivering scientific Enterprise Lab Informatics workflows and software via global support teams
75%
Market presence and customer loyalty. 15 of the top 20 biopharma are 10+ year customers1
Rank measured by Market Cap, Q3 2024 & 2025. Data on file
Top Awards
Industry-recognized, award-winning products2
Top Life Sciences Informatics Company in Europe (Life Sciences Review), Best Biologics Digitalisation Award: Data Analytics for Quality Processes (Asia Pacific Biologics CMO Excellence Awards), Top Laboratory Automation Solutions Companies (pharmatechoutlook.com), Best Bioprocessing Supplier Award: Software, at the prestigious Asia Pacific Biopharma Excellence Awards (ABEA) 2025.
Customer
Satisfaction
Highest satisfaction and most used scientific lab data platform3
IDBS Market Research study with 856 respondents using ten comparable scientific lab data platforms, 2025.
GxP
Excellence
Top rated for GxP compliance support & experience4
Market research study comparing IDBS to seven other comparable software vendors used in Research & Development, Preclinical CROs and Process Development. Data on file.
Quality
Standards
ISO, SOC & ESG certifications. Platinum pharma supplier status5
Awarded platinum pharma supplier status by Qualifyze, the world’s leading third-party audit provider for healthcare and pharma companies, 2025.
Frequently Asked Questions
How do you navigate GxP compliance?
The United States @FDA (Food and Drug Administration) issues guidelines to ensure the quality, safety and effectiveness of new drugs. In 2024, the US FDA issued 190 warning letters to drug and biologic manufacturers, more than double that of the previous year.[i]
Complying with regulatory guidelines, such as those set out by the FDA, can be an administrative burden, especially with the added pressure that non-compliance could result in costly and damaging regulatory warnings, product recalls and / or legal actions.
How can you achieve GxP compliance with confidence? Read the article for our top tips.
How do you ensure the accuracy, consistency and security of data across different stages of your workflows?
The FDA’s Good Manufacturing Practices (GMP) regulations emphasize the importance of accurate and reliable data that is readily available.[ii] Managing large volumes of complex data across unconnected or partially integrated data management systems hinders data integrity, consistency and real-time access.
By centralizing data management in a single digital platform, it is possible to ensure data accuracy and security throughout the product and process lifecycle. Platforms that offer comprehensive audit trails, real-time monitoring and automated data validation not only ensure complete data traceability but also enhance data quality–both of which are essential for supporting rigorous quality assurance (QA) processes.
How do you manage and maintain compliance in line with evolving regulatory requirements?
Maintaining GxP compliance and being inspection-ready can be challenging due to inconsistent data practices and decentralized or partially integrated records, especially when business requirements and strategic plans for the data generated can change to address industry trends and technological advances.
Implementing quality systems with comprehensive documentation, electronic signatures and secure data storage can help you meet complex regulatory requirements and stay inspection-ready, reducing the risk of non-compliance. Systems like IDBS Polar, that provide these features, can help scientists reduce their time on compliance activities by 60%.[iii]
At IDBS, we are conscious of the pressures of keeping pace with current regulatory best practices and understanding how to apply them appropriately. That’s why we set up the GxP Guild: an internal cross-functional team, comprising members from engineering, product and customer support, that meets bi-weekly to discuss how IDBS can respond to new compliance challenges and quickly bring those to market.
How to optimize operational efficiency with electronic systems?
Manual intervention in routine QA tasks slows processes and increases the risk of human error. As the entire drug development process, including QA activities, can take 10-15 years, it’s crucial that BioPharma companies work to streamline these operations by automating where possible.[iv]
Digital platforms improve workflow efficiency through the advanced automation of complex QA tasks, with systems like IDBS Polar potentially reducing QA time by 75%.[v] Real-time data analysis, reporting and predictive analytics provide actionable insights which allow QA teams to proactively address potential issues before they impact operations, reducing bottlenecks and enhancing productivity.
What is the key to continuous improvement?
A recent market survey conducted by IDBS revealed that 26% of BioPharma professionals identify data silos as the most common challenge when working with scientific lab data platforms. [vi] Siloed data and ineffective communication channels significantly hinder cross-functional collaboration and slow down decision-making.
To overcome these barriers, organizations need systems that provide fast, easy access to historical data and are designed to embed best practices and insights through product and process reports. Platforms that enable real-time data sharing and collaborative review processes not only break down silos but also ensure that all teams are working from the same data foundation—promoting alignment with QA objectives and fostering a culture of continuous improvement.
[i] Oestreich L, Auchincloss K, Hartmann E. Trends in FDA FY 2024 inspection-based warning letters. Trends In FDA FY 2024 Inspection-Based Warning Letters. March 7, 2025. Accessed May 6, 2025. https://www.pharmaceuticalonline.com/doc/trends-in-fda-fy-2024-inspection-based-warning-letters-0001.
[ii] Center for Drug Evaluation and Research. Data integrity and compliance with drug CGMP: Questions and answers. U.S. Food and Drug Administration. Accessed May 7, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers.
[iii] Data on file at IDBS.
[iv] Drug development process. MS Trust. January 1, 2021. Accessed May 7, 2025. https://mstrust.org.uk/a-z/drug-development-process.
[v] Data on file at IDBS.
[vi] N = 856 respondents using scientific lab data platforms, IDBS Market Research Study, 2025.
* Data on file at IDBS.